SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC — Stella

Recruiting

Back to Rectal Cancer, Adenocarcinoma trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

Hongli Liu, Wuhan

Key details

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Enrollment target

~49 participants

Started

November 2025

Primary completion

March 2028

Age range

18 Years – 75 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov